Related Articles
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
Oncotype testing in patients undergoing intraoperative radiation for breast cancer
Oncotype DX 21‑gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma
Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer Corrigendum in /10.3892/ol.2021.12572